As of 2026-09-12, the Intrinsic Value of Eagle Pharmaceuticals Inc (EGRX) is 75.87 USD. This EGRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.75 USD, the upside of Eagle Pharmaceuticals Inc is 10,016.20%.
The range of the Intrinsic Value is 61.93 - 98.20 USD
Based on its market price of 0.75 USD and our intrinsic valuation, Eagle Pharmaceuticals Inc (EGRX) is undervalued by 10,016.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 61.93 - 98.20 | 75.87 | 10016.2% |
| DCF (Growth 10y) | 70.33 - 107.76 | 84.77 | 11203.0% |
| DCF (EBITDA 5y) | 75.99 - 117.80 | 89.25 | 11799.4% |
| DCF (EBITDA 10y) | 81.26 - 123.49 | 95.08 | 12577.9% |
| Fair Value | 40.65 - 40.65 | 40.65 | 5,320.30% |
| P/E | 24.15 - 57.89 | 36.21 | 4727.5% |
| EV/EBITDA | 80.67 - 193.82 | 119.23 | 15797.9% |
| EPV | 56.64 - 72.54 | 64.59 | 8512.2% |
| DDM - Stable | 3.07 - 5.98 | 4.52 | 502.7% |
| DDM - Multi | 5.19 - 8.78 | 6.59 | 778.8% |
| Market Cap (mil) | 6.81 |
| Beta | -7.59 |
| Outstanding shares (mil) | 9.08 |
| Enterprise Value (mil) | 61.61 |
| Market risk premium | 4.60% |
| Cost of Equity | 25.75% |
| Cost of Debt | 5.00% |
| WACC | 5.17% |